Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDAS frontline MRD-adapted strategy study in transplant-eligible newly diagnosed multiple myeloma
2020-005216-21Phase 3Active
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of isatuximab, iberdomide, carfilzomib and lenalidomide in multiple myeloma (MM) (4 arms), sponsored by Inter-Groupe Francophone du Myélome. Primary endpoint: MRD negativity before maintenance. Started May 2021; status: active.
02
Drugs
isatuximabiberdomidecarfilzomiblenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-005216-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005216-21.